ABSTRACT:

Type 2 diabetes is a lifelong disease. It has to do with the way your body metabolizes blood sugar. It’s known as being insulin-resistant – meaning the cells in your body don’t respond well to insulin – and eventually as an insulin deficiency. Nobody knows exactly what causes it, but factors include genetics, obesity, no physical activity, and a junk food diet. symptoms are: increased thirst; frequent urination; extreme fatigue; blurred vision; slow healing of wounds. Most people who have type 2 diabetes find out when they have this blood test done or when they have a test that uses their blood. There is no cure for diabetes but you can control it by changing your lifestyle – eating healthy foods, exercising, and keeping a healthy weight. Oftentimes, though, medicines or insulin injections are needed to help with the disease. Prevention: Maintaining a healthy weight, eating a balanced diet rich in whole foods, engaging in regular physical activity, Avoiding smoking and excessive alcohol consumption. Type 2 diabetes is a manageable condition, and early intervention can significantly improve outcomes and quality of life. 

KEYWORDS:

Type 2 Diabetes, insulin, Beta -cells..

REFFERENCES 

1) NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet 2016; 387: 1513–30
2) GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990– 2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–602.
3) Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics 2015; 33: 811–31.
4) WHO. Non-communicable diseases country profi le 2014. July, 2014. http://www.who.int/nmh/publications/ncd-profi les-2014/en/ (accessed Oct 6, 2016)
5) Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93.
6) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
7) ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.
8) Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–39.
9) Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.
10) Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008–17
11) Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientifi c statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32: 187–92
12) Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med 2008; 358: 2633–35.
13) Elwen FR, Huskinson A, Clapham L, et al. An observational study of patient characteristics and mortality following hypoglycemia in the community. BMJ Open Diabetes Res Care 2015; 3: e000094
14) Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic signifi cance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014; 63: 1228–37
15) Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roque I Figuls M, Richter B, Mauricio D. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; 3: CD003054
16) Merlotti C, Morabito A, Pontiroli AE. Prevention of type 2 diabetes; a systematic review and meta-analysis of diff erent intervention strategies. Diabetes Obes Metab 2014; 16: 719–27
17) Diabetes Prevention Program Research Group. Long-term eff ects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015; 3: 866–75.
18) Perreault L, Temprosa M, Mather KJ, et al. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care 2014; 37: 2622–31
19) Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population-based cohort study. BMJ 2016; 352: i1541.
20) Nauck MA, Meier JJ. The incretin effs ect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 2016; 4: 525–36
21) Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473–81
22) Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559–69
23) Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M; Consensus Workshop Group. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. 2004; 27:1798–1811. doi: 10.2337/diacare.27.7.1798
24) Koopman RJ, Mainous AG 3rd, Diaz VA, Geesey ME. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med. 2005; 3:60–63. doi: 10.1370/afm.214
25) Grinstein G, Muzumdar R, Aponte L, Vuguin P, Saenger P, DiMartino-Nardi J. Presentation and 5-year follow-up of type 2 diabetes mellitus in AfricanAmerican and Caribbean-Hispanic adolescents. Horm Res. 2003; 60:121– 126. doi: 10.1159/000072523
26) JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100(suppl 2): ii1– ii67. doi: 10.1136/heartjnl-2014-305693
27) U.S. Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease. A report of the Surgeon General. Atlanta, Ga., Centers for Disease Control and Prevention, 2010
28) Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr 2013; 97:505–516
29) Stewart A, Kamberg CJ. Physical functioniong measures. In Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Stewart A, Ware JE, Eds. Durham, N.C., Duke University Press, 1992, p. 86–101
30) Krug LM, Haire-Joshu D, Heady SA. Exercise habits and exercise relapse in persons with non-insulin-dependent diabetes mellitus. Diabetes Educ 1991; 17:185–188